PCVX Q2 2020 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena

PCVXVaxcyte, Inc.

$8B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$21M

Net Income

-$20M

EPS (Diluted)

$-0.42

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$416M

Total Liabilities

$33M

Stockholders' Equity

$383M

Cash & Equivalents

$410M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$21M	-$12M	-73.5%
Net Income	-$20M	-$11M	-90.5%

Revenue Segments

Pneumococcal Conjugate Vaccine

$7.0B100%